IL32 overexpression
|
Melanoma
|
IL32 overexpression
|
Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
IL32 overexpression
|
Melanoma
|
IL32 overexpression
|
Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|